

Olaparib for Metastatic Castration-Resistant Prostate C

New England Journal of Medicine

382, 2091-2102

DOI: [10.1056/nejmoa1911440](https://doi.org/10.1056/nejmoa1911440)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Recent advancements in PARP inhibitors-based targeted cancer therapy. Precision Clinical Medicine, 2020, 3, 187-201.	1.3	26
2	Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome. JCO Precision Oncology, 2020, 4, 841-847.	1.5	4
3	Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecologic Oncology, 2020, 159, 887-898.	0.6	70
4	Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. Cancers, 2020, 12, 2855.	1.7	16
5	Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Lung Cancer, 2020, 150, 62-69.	0.9	15
6	Survival benefits of PARP inhibitors in advanced breast cancer: aÂmirage?. Annals of Oncology, 2020, 31, 1432-1434.	0.6	4
8	Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. PLoS ONE, 2020, 15, e0239686.	1.1	6
9	CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clinical and Translational Radiation Oncology, 2020, 25, 61-66.	0.9	15
10	Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2. Cancers, 2020, 12, 2834.	1.7	6
11	Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data. Targeted Oncology, 2020, 15, 709-722.	1.7	17
12	Precision Oncology for Metastatic Prostate Cancer: Translation into Practice. European Urology, 2020, 78, 771-774.	0.9	3
13	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 2020, 31, 1491-1505.	0.6	658
14	The DNA damaging revolution. Critical Reviews in Oncology/Hematology, 2020, 156, 103117.	2.0	9
15	Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer. Clinical Cancer Research, 2020, 26, 4869-4881.	3.2	18
16	Targeting DNA repair defects in prostate cancer. Nature Reviews Urology, 2020, 17, 432-432.	1.9	4
17	Prostate Cancer 2020: "The Times They Are a-Changing". Cancer Cell, 2020, 38, 25-27.	7.7	18
18	Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. International Journal of Molecular Sciences, 2020, 21, 5036.	1.8	38
19	Cardiovascular Complications of Prostate Cancer Therapy. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.4	6

#	ARTICLE	IF	CITATIONS
20	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020, 1, 1041-1053.	5.7	45
21	Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer. <i>Cells</i> , 2020, 9, 2494.	1.8	13
22	Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2020, 12, 3467.	1.7	13
23	A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?. <i>European Urology Oncology</i> , 2021, 4, 745-754.	2.6	17
24	Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 2130-2137.	1.0	2
25	The emerging role of PARP inhibitors in prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 715-726.	1.1	12
26	PARP inhibitors in castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100199.	0.7	12
28	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration. <i>Journal of Clinical Oncology</i> , 2020, 38, 3763-3772.	0.8	448
29	<p>Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 10499-10513.	1.0	16
30	Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 383-400.	0.4	4
31	Novel therapies are changing treatment paradigms in metastatic prostate cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 144.	6.9	80
32	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	0.8	276
33	Resetting the Bar of Castration Resistance – Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 199-207.	0.9	7
34	<i>BRCA1</i> Versus <i>BRCA2</i> and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?. <i>Journal of Clinical Oncology</i> , 2020, 38, 3735-3739.	0.8	38
35	Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer. <i>Diagnostics</i> , 2020, 10, 658.	1.3	7
36	BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. <i>Journal of Oncology</i> , 2020, 2020, 1-7.	0.6	58
37	<p>PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 8105-8114.	0.9	58
38	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2345-2357.	13.9	440

#	ARTICLE	IF	CITATIONS
39	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 890-891.	13.9	9
40	Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives. <i>Cancers</i> , 2020, 12, 2414.	1.7	10
41	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020, 80, 1273-1296.	1.2	16
42	Germline mutations and prostate cancer: is it time to change treatment algorithms?. <i>Chinese Clinical Oncology</i> , 2020, 9, 65-65.	0.4	2
43	Poly (ADP-Ribose) Polymerase Inhibitor Activity in Prostate Cancers Harboring Mutations in DNA Repair Genes: Who Benefits?. <i>JCO Precision Oncology</i> , 2020, 4, 1034-1037.	1.5	6
44	Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2020, 38, 3740-3742.	0.8	14
45	Somatic Testing and Germline Genetic Status: Implications for Cancer Treatment Decisions and Genetic Counseling. <i>Current Genetic Medicine Reports</i> , 2020, 8, 109-119.	1.9	0
46	Mutations in ATM , NBN and BRCA2 predispose to aggressive prostate cancer in Poland. <i>International Journal of Cancer</i> , 2020, 147, 2793-2800.	2.3	27
47	PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 564601.	1.8	315
48	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. <i>Lancet Oncology</i> , The, 2020, 21, 1513-1525.	5.1	35
49	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3672-3684.	0.8	78
50	When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. <i>European Urology Oncology</i> , 2020, 3, 594-611.	2.6	63
51	Targeting defective DNA repair in prostate cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 503-509.	1.1	4
52	<p>Metastatic Castration-Resistant Prostate Cancer with Neuroendocrine Transformation and BRCA 1 Germ-Line Mutation: A Case Report and Literature Review</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8049-8054.	1.0	8
53	Neuroendocrine and Aggressive-Variant Prostate Cancer. <i>Cancers</i> , 2020, 12, 3792.	1.7	42
54	Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients. <i>Cancers</i> , 2020, 12, 3846.	1.7	5
55	Management of Advanced Prostate Cancer in Clinical Practice: Real-World Answers to Challenging Dilemmas. <i>JCO Oncology Practice</i> , 2020, 16, 783-789.	1.4	6
57	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020, 3, e2021692.	2.8	70

#	ARTICLE	IF	CITATIONS
58	Pharmacokinetic drug-drug interactions: an insight into recent US FDA-approved drugs for prostate cancer. <i>Bioanalysis</i> , 2020, 12, 1647-1664.	0.6	7
59	Homologous Recombination DNA Repair Gene Aberrations—Are We More Alike Than Different?. <i>JAMA Network Open</i> , 2020, 3, e2021717.	2.8	0
60	PARP inhibitors in prostate cancer: time to narrow patient selection?. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 523-526.	1.1	4
61	Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. <i>Carcinogenesis</i> , 2020, 41, 904-908.	1.3	1
62	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1119-1134.	0.6	485
63	Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 136, 16-24.	1.3	41
64	The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100190.	0.7	0
65	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. <i>Cells</i> , 2020, 9, 1522.	1.8	6
66	Re: Olaparib for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 78, 767-768.	0.9	2
67	Re: Platinum-based Chemotherapy in Metastatic Prostate Cancer with DNA Repair Gene Alterations. <i>European Urology</i> , 2020, 78, 768-770.	0.9	2
68	DNA Repair and Prostate Cancer: A Field Ripe for Harvest. <i>European Urology</i> , 2020, 78, 486-488.	0.9	19
69	Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II/III randomized controlled trials. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 241-255.	0.7	10
70	A CHIP in the Armor of Cell-Free DNA-Based Predictive Biomarkers for Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 111.	3.4	2
71	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. <i>European Urology</i> , 2021, 79, 200-211.	0.9	76
72	Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. <i>European Urology</i> , 2021, 79, 442-445.	0.9	41
73	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	0.9	633
74	Re: Olaparib for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2021, 79, 319-320.	0.9	0
76	<sc>PARP</sc> inhibition in prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 344-351.	1.5	2

#	ARTICLE	IF	CITATIONS
77	PARP Inhibitors in Cancer Diagnosis and Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 1585-1594.	3.2	53
78	A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. <i>Annals of Oncology</i> , 2021, 32, 103-112.	0.6	98
79	To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 389-400.	1.1	2
80	Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 301-309.	2.0	19
81	TP53 alterations of hormone-naïve prostate cancer in the Chinese population. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 482-491.	2.0	21
82	Molecular pathology of prostate cancer: a practical approach. <i>Pathology</i> , 2021, 53, 36-43.	0.3	17
83	Current and emerging therapies for localized high-risk prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 267-282.	1.1	3
84	Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 176-190.	157.7	101
85	Loose Regulatory Standards Portend a New Era of Imprecision Oncology. <i>Cancer Investigation</i> , 2021, 39, 1-4.	0.6	1
86	Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case. <i>IJU Case Reports</i> , 2021, 4, 14-17.	0.1	4
87	Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. <i>British Journal of Cancer</i> , 2021, 124, 552-563.	2.9	63
88	Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patients. <i>BJUI Compass</i> , 2021, 2, 31-38.	0.7	4
89	Nanomedicine for the Treatment of Advanced Prostate Cancer. <i>Advanced Therapeutics</i> , 2021, 4, 2000136.	1.6	3
90	Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 385-395.	2.3	28
91	PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA. <i>Oncologist</i> , 2021, 26, e115-e129.	1.9	51
92	Autophagy and PTEN in DNA damage-induced senescence. <i>Advances in Cancer Research</i> , 2021, 150, 249-284.	1.9	13
93	Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100328.	0.7	70
94	Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 558-566.	2.0	9

#	ARTICLE	IF	CITATIONS
95	A marrow-minded look at immune checkpoint blockade resistance in metastatic castration resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 4009-4013.	0.6	0
96	Perspectives in immunotherapy: meeting report from the "ImmunoTherapy Bridge" (December 4th-5th,) <i>TJ</i> 11, 0, 784314	1.8	3
97	Differential expression of α 3 and α 6 integrins in prostate cancer progression. <i>PLoS ONE</i> , 2021, 16, e0244985.	1.1	16
98	Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. <i>Modern Pathology</i> , 2021, 34, 1185-1193.	2.9	61
99	Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 571-584.	0.7	26
100	Genomic Profiling of Prostate Cancer: An Updated Review. <i>World Journal of Men's Health</i> , 2022, 40, 368.	1.7	19
101	Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 610601.	1.6	13
102	Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 334.	1.7	44
103	Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. <i>JAMA Oncology</i> , 2021, 7, 107.	3.4	90
104	The role of liquid biopsies in prostate cancer management. <i>Lab on A Chip</i> , 2021, 21, 3263-3288.	3.1	9
105	Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review. <i>Future Oncology</i> , 2021, 17, 91-102.	1.1	4
106	Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?. <i>Cancers</i> , 2021, 13, 327.	1.7	27
107	PARP Inhibitors in Prostate Cancer. <i>Anticancer Research</i> , 2021, 41, 551-556.	0.5	15
108	Current Status of Castration-Resistant Prostate Cancer Drug Therapy. <i>International Journal of Surgery Oncology</i> , 2021, 6, 41-49.	0.2	3
109	Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3931-3945.	0.6	3
110	<i>BRCA2</i> , <i>ATM</i> , and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. <i>Clinical Cancer Research</i> , 2021, 27, 1650-1662.	3.2	52
111	Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. <i>Journal of Urology</i> , 2021, 205, 14-21.	0.2	167
112	Polygenic risk score for genetic evaluation of prostate cancer risk in Asian populations: A narrative review. <i>Investigative and Clinical Urology</i> , 2021, 62, 256.	1.0	7

#	ARTICLE	IF	CITATIONS
113	Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy. <i>Theranostics</i> , 2021, 11, 8143-8151.	4.6	14
114	Clinical implications of genomic alterations in metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 310-322.	2.0	12
115	Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance. <i>BMC Cancer</i> , 2021, 21, 35.	1.1	7
116	SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 969-979.	1.2	18
117	Response to comment on "Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer" <i>European Journal of Cancer</i> , 2021, 144, 395-396.	1.3	0
118	Homologous recombination repair deficiency (HRD): From biology to clinical exploitation. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 299-302.	1.5	16
119	Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. <i>Lancet Haematology</i> , 2021, 8, e122-e134.	2.2	139
120	International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review. <i>Onkourologiya</i> , 2021, 16, 197-206.	0.1	3
121	From Race-Based to Precision Oncology: Leveraging Behavioral Economics and the Electronic Health Record to Advance Health Equity in Cancer Care. <i>JCO Precision Oncology</i> , 2021, 5, 403-407.	1.5	3
122	Treatment-emergent neuroendocrine prostate cancer with a germline <i>BRCA2</i> mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a005801.	0.5	9
123	Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2100.	1.8	13
124	Cancer de prostata. <i>Medicine</i> , 2021, 13, 1454-1466.	0.0	0
125	Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer. <i>Diagnostics</i> , 2021, 11, 345.	1.3	14
126	Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 779.	1.7	45
127	Treating Prostate Cancer by Antibody-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1551.	1.8	38
128	Molecular and metabolic imaging of castration-resistant prostate cancer: state of art and future prospects. <i>Current Molecular Medicine</i> , 2021, 21, .	0.6	1
129	Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials. <i>Journal of Chemotherapy</i> , 2021, 33, 452-461.	0.7	5
130	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 311-325.	1.3	19

#	ARTICLE	IF	CITATIONS
131	Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review. <i>World Journal of Urology</i> , 2021, 39, 3177-3185.	1.2	7
132	Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation. <i>Cancers</i> , 2021, 13, 1004.	1.7	28
133	Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 1-9.	2.6	27
135	Next-Generation Androgen Receptor-Signaling Inhibitors for Prostate Cancer: Considerations for Older Patients. <i>Drugs and Aging</i> , 2021, 38, 111-123.	1.3	8
136	Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies. <i>Cancer Reports</i> , 2021, 4, e1340.	0.6	13
137	Prostate cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, 9.	18.1	434
138	SWATH-MS Based Proteomic Profiling of Prostate Cancer Cells Reveals Adaptive Molecular Mechanisms in Response to Anti-Androgen Therapy. <i>Cancers</i> , 2021, 13, 715.	1.7	9
139	Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. <i>Cureus</i> , 2021, 13, e13199.	0.2	0
140	Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1970-1980.	2.8	4
141	Glycogen synthase kinase 3 β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer. <i>Cell Death and Disease</i> , 2021, 12, 183.	2.7	15
142	Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease. <i>Cancers</i> , 2021, 13, 760.	1.7	22
143	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 134-143.	2.3	299
144	Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.09.024 . <i>European Urology</i> , 2021, 79, e83-e84.	0.9	0
145	Differential treatment outcomes in <i>BRCA1/2</i> , <i>CDK12</i> , and <i>ATM</i> mutated metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 1965-1973.	2.0	15
146	Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 25-37.	1.1	19
147	Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 473-487.	12.5	139
148	How Does Endometriosis Lead to Ovarian Cancer? The Molecular Mechanism of Endometriosis-Associated Ovarian Cancer Development. <i>Cancers</i> , 2021, 13, 1439.	1.7	19
149	Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. <i>Nature Communications</i> , 2021, 12, 1426.	5.8	176

#	ARTICLE	IF	CITATIONS
150	Total Synthesis and Target Identification of the Curcusone Diterpenes. <i>Journal of the American Chemical Society</i> , 2021, 143, 4379-4386.	6.6	23
151	Novel Strategies for Treating Castration-Resistant Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 339.	1.4	14
152	Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. <i>JCO Precision Oncology</i> , 2021, 5, 533-542.	1.5	6
153	Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer's Achilles Heel. <i>Cancers</i> , 2021, 13, 1392.	1.7	29
154	A narrative review of individualized treatments of genitourinary tumors: is the future brighter with molecular evaluations?. <i>Translational Andrology and Urology</i> , 2021, 10, 1553-1561.	0.6	5
155	How Macrophages Become Transcriptionally Dysregulated: A Hidden Impact of Antitumor Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2662.	1.8	11
156	Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3201-3214.	3.2	27
157	Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 451-461.	1.9	6
158	Resistance to second-generation androgen receptor antagonists in prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 209-226.	1.9	59
159	PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival. <i>Aging</i> , 2021, 13, 8975-8988.	1.4	13
160	Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1040-1050.	1.5	17
161	Volume matters and intensification is needed: emerging trends in the management of advanced prostate cancer. <i>Drugs in Context</i> , 2021, 10, 1-15.	1.0	0
162	How I Treat Metastatic Hormone-Sensitive Prostate Cancer?. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 100-107.	0.1	0
163	Effects of Medical Treatment of Prostate Cancer on Bone Health. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 135-158.	3.1	21
164	Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naïve disease. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1287-1297.	0.6	1
165	Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study. <i>Cancers</i> , 2021, 13, 1284.	1.7	6
166	Epidemiology and genomics of prostate cancer in Asian men. <i>Nature Reviews Urology</i> , 2021, 18, 282-301.	1.9	111
167	Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment. <i>Oncologist</i> , 2021, 26, 537-548.	1.9	8

#	ARTICLE	IF	CITATIONS
168	Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1174-1176.	13.9	1
169	Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.09.024 . <i>European Urology</i> , 2021, 79, e81-e82.	0.9	1
170	Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal. <i>Current Opinion in Oncology</i> , 2021, 33, 252-256.	1.1	3
171	Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays. <i>British Journal of Cancer</i> , 2021, 125, 7-14.	2.9	14
172	Identification of a DNA Repair Gene Signature and Establishment of a Prognostic Nomogram Predicting Biochemical-Recurrence-Free Survival of Prostate Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 608369.	1.6	8
173	Routine application of next-generation sequencing testing in uro-oncology—Are we ready for the next step of personalised medicine?. <i>European Journal of Cancer</i> , 2021, 146, 1-10.	1.3	5
174	Prostate cancer and PARP inhibitors: progress and challenges. <i>Journal of Hematology and Oncology</i> , 2021, 14, 51.	6.9	68
175	A New Insight for the Identification of Oncogenic Variants in Breast and Prostate Cancers in Diverse Human Populations, With a Focus on Latinos. <i>Frontiers in Pharmacology</i> , 2021, 12, 630658.	1.6	3
176	Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4712.	1.8	14
178	Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management. <i>Cancers</i> , 2021, 13, 2154.	1.7	13
179	Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1625-1632.	0.9	5
180	Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer. <i>Clinical Trials</i> , 2021, 18, 408-416.	0.7	4
181	Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3753.	1.8	61
182	Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCDC). <i>JCO Global Oncology</i> , 2021, 7, 559-571.	0.8	10
183	Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. <i>European Urology</i> , 2021, 79, 519-529.	0.9	30
185	An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer. <i>ESMO Open</i> , 2021, 6, 100089.	2.0	4
186	The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology. <i>Journal of Personalized Medicine</i> , 2021, 11, 330.	1.1	1
187	Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis. <i>Annals of Pharmacotherapy</i> , 2022, 56, 27-34.	0.9	2

#	ARTICLE	IF	CITATIONS
188	Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e508-e528.	2.4	36
189	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , 2021, 81, 433-439.	1.2	29
190	Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. <i>Cancers</i> , 2021, 13, 1861.	1.7	4
191	Changing the History of Prostate Cancer with New Targeted Therapies. <i>Biomedicines</i> , 2021, 9, 392.	1.4	16
192	Resistance to the Androgen Receptor Centred Therapies: Biology and Management. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1593-1609.	0.3	0
193	Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 622-637.	1.5	18
194	Synthetic Lethality in Cancer Therapeutics: The Next Generation. <i>Cancer Discovery</i> , 2021, 11, 1626-1635.	7.7	91
195	Clinical significance of mutations in DNA repair genes in patients with metastatic prostate cancer. <i>Onkourologiya</i> , 2021, 17, 82-88.	0.1	0
196	Recent Advances in the Treatment of Metastatic Prostate Cancer. <i>Advances in Oncology</i> , 2021, 1, 263-272.	0.1	1
197	Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine. <i>Frontiers in Oncology</i> , 2021, 11, 675311.	1.3	6
198	Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From "All-Comers" to "Personalized" Approach. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2967-2974.	1.0	11
199	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. <i>Cancer Discovery</i> , 2021, 11, 2812-2827.	7.7	78
200	Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer. <i>BMC Cancer</i> , 2021, 21, 611.	1.1	5
201	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021, 12, 2487.	5.8	116
202	PALB2 mutations and prostate cancer risk and survival. <i>British Journal of Cancer</i> , 2021, 125, 569-575.	2.9	18
203	Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies. <i>Oncologist</i> , 2021, 26, e1179-e1188.	1.9	2
204	Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	20
206	Emerging biological therapies for the treatment of malignant pleural mesothelioma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 179-192.	1.0	3

#	ARTICLE	IF	CITATIONS
207	PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation. <i>Genes</i> , 2021, 12, 849.	1.0	10
208	Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice. <i>JCO Precision Oncology</i> , 2021, 5, 884-895.	1.5	21
209	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5522.	1.8	12
210	Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. <i>Journal of Clinical Oncology</i> , 2021, 39, 1631-1640.	0.8	62
211	2020 Korean guidelines for the management of metastatic prostate cancer. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 491-514.	0.7	5
213	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. <i>Genome Medicine</i> , 2021, 13, 96.	3.6	26
214	A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer. <i>The Application of Clinical Genetics</i> , 2021, Volume 14, 255-266.	1.4	0
215	Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2110950.	2.8	4
216	Biomarker approach harnessed in trials of personalized medicine for bladder cancer. <i>Nature Medicine</i> , 2021, 27, 761-763.	15.2	5
217	Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair Mutations. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e352-e359.	0.9	0
218	Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity. <i>Cancers</i> , 2021, 13, 2249.	1.7	28
219	BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored. <i>Diagnostics</i> , 2021, 11, 908.	1.3	26
220	Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. <i>Pharmaceutics</i> , 2021, 13, 722.	2.0	25
221	<i>BRCA</i> mutated pancreatic cancer: A change is coming. <i>World Journal of Gastroenterology</i> , 2021, 27, 1943-1958.	1.4	42
222	Bee Venom Components as Therapeutic Tools against Prostate Cancer. <i>Toxins</i> , 2021, 13, 337.	1.5	19
223	Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, 101-111.	0.3	10
224	Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. <i>Seminars in Cancer Biology</i> , 2022, 84, 242-254.	4.3	22
225	Precision Oncology. <i>Advances in Oncology</i> , 2021, 1, 97-112.	0.1	0

#	ARTICLE	IF	CITATIONS
226	Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management. <i>European Urology Focus</i> , 2021, 7, 513-521.	1.6	0
227	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 149, 134-152.	1.3	41
228	Protein kinase inhibitors for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1889-1899.	0.9	8
229	Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer. <i>Current Molecular Pharmacology</i> , 2021, 14, .	0.7	3
230	Prostate Cancer Immunotherapyâ€”Finally in From the Cold?. <i>Current Oncology Reports</i> , 2021, 23, 88.	1.8	21
231	Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-23.	0.9	3
232	The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?. <i>ESMO Open</i> , 2021, 6, 100144.	2.0	77
233	PARP inhibitor treatment of advanced breast cancer beyond the <i>BRCA</i>-mutated type: a meta-analysis. <i>Future Oncology</i> , 2021, 17, 2381-2393.	1.1	7
234	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. <i>Cancers</i> , 2021, 13, 2776.	1.7	9
235	An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers. <i>Cancers</i> , 2021, 13, 3113.	1.7	0
236	Prevalence of DNA Repair Gene Mutations in Blood and Tumor Tissue and Impact on Prognosis and Treatment in HNSCC. <i>Cancers</i> , 2021, 13, 3118.	1.7	11
237	PARP inhibitors beyond BRCA-mutated cancers: precision medicine at the crossroads. <i>Precision Cancer Medicine</i> , 0, 4, 19-19.	1.8	2
238	Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e190-e202.	1.8	9
239	ATR Inhibition Induces CDK1â€”SPOP Signaling and Enhances Antiâ€”PD-L1 Cytotoxicity in Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4898-4909.	3.2	66
240	Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1102-1110.	0.5	1
241	An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 631-640.	1.5	4
242	Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 199-207.	2.0	3
243	Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. <i>Annals of Oncology</i> , 2021, 32, 726-735.	0.6	22

#	ARTICLE	IF	CITATIONS
244	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 518.	1.1	8
245	First international workshop of the ATM and cancer risk group (4-5 December 2019). <i>Familial Cancer</i> , 2022, 21, 211-227.	0.9	10
246	Molecular Characterization of Muellierian Tumors of the Urinary Tract. <i>Genes</i> , 2021, 12, 880.	1.0	5
247	Detection of actionable mutations in archived cytological bile specimens. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 837-847.	1.4	8
248	Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3895-3901.	1.0	9
249	Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer. <i>Mechanisms of Ageing and Development</i> , 2021, 196, 111494.	2.2	4
250	Global experience with PSMA-based alpha therapy in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 30-46.	3.3	27
251	Pandemic Spread of COVID-19 Mutant Variants Will Facilitate Next-generation Sequencing Capacities for Personalised Medicine in Urologic Oncology. <i>European Urology</i> , 2021, 79, 895-896.	0.9	0
252	Canadian consensus forum of key controversial areas in the management of advanced prostate cancer. <i>Canadian Urological Association Journal</i> , 2021, 15, 353-358.	0.3	2
253	High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. <i>SLAS Discovery</i> , 2021, 26, 1107-1124.	1.4	30
254	Immediate and Long-Term Outcomes of Reperfusion Therapy in Patients With Cancer. <i>Stroke</i> , 2021, 52, 2026-2034.	1.0	21
255	NPRL2 reduces the niraparib sensitivity of castration-resistant prostate cancer via interacting with UBE2M and enhancing neddylation. <i>Experimental Cell Research</i> , 2021, 403, 112614.	1.2	5
256	Metastatic Prostate Cancer Synchronous with Male Breast Papillary Ductal Carcinoma in situ: Management Dilemma and Literature Review. <i>Case Reports in Oncology</i> , 2021, 14, 784-791.	0.3	1
257	Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?. <i>European Urology</i> , 2021, 79, 710-712.	0.9	9
259	¹⁷⁷ Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements. <i>Annals of Nuclear Medicine</i> , 2021, 35, 861-870.	1.2	2
260	Olaparib for the treatment of metastatic prostate cancer. <i>Future Oncology</i> , 2021, 17, 2413-2429.	1.1	2
261	Current Understanding and Management of Intraductal Carcinoma of the Prostate. <i>Current Oncology Reports</i> , 2021, 23, 110.	1.8	1
262	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. <i>JAMA Network Open</i> , 2021, 4, e2114753.	2.8	15

#	ARTICLE	IF	CITATIONS
263	Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management. <i>Cancers</i> , 2021, 13, 3556.	1.7	9
264	Differential Activity of PARP Inhibitors in <i>BRCA1</i> - Versus <i>BRCA2</i> -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1200-1220.	1.5	17
265	Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 564.e1-564.e10.	0.9	4
266	Association of germline ATM mutations and survival in pancreatic cancer. <i>Annals of Pancreatic Cancer</i> , 0, 4, 1-1.	1.2	1
267	BRCA mutations and gastrointestinal cancers: When to expect the unexpected?. <i>World Journal of Clinical Oncology</i> , 2021, 12, 565-580.	0.9	10
269	Association of intraductal carcinoma of the prostate detected by initial histological specimen and neuroendocrine prostate cancer: A report of three cases. <i>Pathology International</i> , 2021, 71, 621-626.	0.6	1
270	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 773-791.	12.5	198
271	Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors. <i>Advances in Therapy</i> , 2021, 38, 4520-4540.	1.3	32
272	Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 8.e11-8.e18.	0.8	8
273	Technical and biological constraints on ctDNA-based genotyping. <i>Trends in Cancer</i> , 2021, 7, 995-1009.	3.8	33
274	The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 871-878.	2.3	10
275	Regulations, Open Data and Healthcare Innovation: A Case of MSK-IMPACT and Its Implications for Better Cancer Care. <i>Cancers</i> , 2021, 13, 3448.	1.7	2
276	B2B: Prostate Cancer. <i>Soci�t� Internationale D'urologie Journal</i> , 2021, 2, S30-S50.	0.2	0
277	Overview of Olaparib as a treatment option for metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1955-1959.	0.9	0
278	A transcriptomic model for homologous recombination deficiency in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 659-665.	2.0	9
279	Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7884.	1.8	8
280	Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis. <i>Prostate</i> , 2021, 81, 1091-1096.	1.2	1
281	Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer. <i>Cancer Medicine</i> , 2021, 10, 5574-5588.	1.3	11

#	ARTICLE	IF	CITATIONS
282	Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives. <i>Cancers</i> , 2021, 13, 3715.	1.7	11
283	Multi-gene mutation metastatic castrate-resistant prostate cancer. <i>BMJ Case Reports</i> , 2021, 14, e243124.	0.2	1
284	Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation. <i>Cancers</i> , 2021, 13, 3471.	1.7	9
285	Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance. <i>Trends in Molecular Medicine</i> , 2021, 27, 630-642.	3.5	18
286	Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database. <i>Gynecologic Oncology</i> , 2021, 162, 496-505.	0.6	19
287	Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs. <i>JCO Precision Oncology</i> , 2021, 5, 1377-1386.	1.5	5
288	PSMA Theranostics: Current Landscape and Future Outlook. <i>Cancers</i> , 2021, 13, 4023.	1.7	33
289	Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 2617-2631.	0.8	63
290	Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality. <i>European Urology Oncology</i> , 2021, 4, 674-675.	2.6	2
291	Genetic Contribution to Metastatic Prostate Cancer. <i>Urologic Clinics of North America</i> , 2021, 48, 349-363.	0.8	0
292	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. <i>Cancer</i> , 2021, 127, 4557-4564.	2.0	5
293	Molecular pathogenesis of hereditary lung cancer: a literature review. <i>Pharmacogenomics</i> , 2021, 22, 791-803.	0.6	2
294	Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention. <i>JCO Precision Oncology</i> , 2021, 5, 1387-1396.	1.5	23
295	BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme. <i>Biomolecules</i> , 2021, 11, 1188.	1.8	13
296	Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	6
297	Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study. <i>Breast Cancer</i> , 2022, 29, 92-102.	1.3	2
298	Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation. <i>Cancers</i> , 2021, 13, 4346.	1.7	15
299	Cytotoxic and targeted therapy for BRCA1/2-driven cancers. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 36.	0.6	11

#	ARTICLE	IF	CITATIONS
300	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. <i>Nature Communications</i> , 2021, 12, 5049.	5.8	33
301	Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). <i>JCO Precision Oncology</i> , 2021, 5, 1432-1442.	1.5	29
303	Overview of Prostate Cancer Genetic Testing. <i>Urologic Clinics of North America</i> , 2021, 48, 279-282.	0.8	0
304	Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 541-553.	1.3	4
305	Rapid Progression of Metastatic Pancreatic Adenocarcinoma During <scp>Platinum-Based</scp> Therapy in a Patient Harboring a Pathogenic <i>BRCA2</i> Germline Variant. <i>Oncologist</i> , 2021, 26, 916-918.	1.9	1
306	RNA Sequencing for Personalized Treatment of Metastatic Leiomyosarcoma: Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 666001.	1.3	6
307	Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1515-1533.	1.2	10
308	Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>. <i>Journal of Clinical Oncology</i> , 2021, 39, 2497-2505.	0.8	113
309	Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions. <i>Oncotarget</i> , 2021, 12, 1600-1614.	0.8	14
310	A Review on the Current Treatment Paradigm in High-Risk Prostate Cancer. <i>Cancers</i> , 2021, 13, 4257.	1.7	10
311	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	0.8	83
312	A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 131-153.	4.2	55
313	Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care. <i>Urologic Clinics of North America</i> , 2021, 48, 311-322.	0.8	2
314	Genetically Informed Prostate Cancer Screening. <i>Urologic Clinics of North America</i> , 2021, 48, 373-386.	0.8	1
315	Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP. <i>European Urology</i> , 2021, 80, 123-126.	0.9	4
316	¹⁷⁷ Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Biomedicines</i> , 2021, 9, 1042.	1.4	10
317	Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study. <i>Pharmaceuticals</i> , 2021, 14, 804.	1.7	13
318	Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer. <i>Cancer Medicine</i> , 2021, 10, 6304-6309.	1.3	3

#	ARTICLE	IF	CITATIONS
319	Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in <i>BRCA1</i>, <i>BRCA2</i> or <i>ATM</i>?. <i>Pharmacogenomics</i> , 2021, 22, 809-819.	0.6	6
320	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. <i>European Urology Oncology</i> , 2021, 4, 570-579.	2.6	38
321	Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives. <i>Breast</i> , 2021, 58, 121-129.	0.9	7
322	CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2140-2150.	1.9	9
323	Black Disparities in Targeted Therapy Clinical Trials – A Call for Future Reset. <i>Journal of Education and Teaching in Emergency Medicine</i> , 2021, 7, 8-28.	0.0	1
324	Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 1004.	1.4	5
325	Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 2907-2921.	1.1	12
326	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. <i>European Urology Open Science</i> , 2021, 30, 47-62.	0.2	2
327	Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 905-914.	2.3	21
329	Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. <i>Cancer Causes and Control</i> , 2021, 32, 1365-1374.	0.8	10
330	Genetically Informed Prostate Cancer Treatment for Metastatic Disease. <i>Urologic Clinics of North America</i> , 2021, 48, 365-371.	0.8	0
331	Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2028-2036.e2.	0.3	17
332	Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. , 2021, 9, e002931.		18
333	Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples. <i>JCO Precision Oncology</i> , 2021, 5, 1312-1324.	1.5	15
334	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 388-396.	2.0	15
335	Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge. <i>European Journal of Cancer</i> , 2021, 155, 163-167.	1.3	7
336	Pan-Cancer Molecular Biomarkers. <i>Surgical Pathology Clinics</i> , 2021, 14, 507-516.	0.7	4
337	Molecular Pathology of Prostate Cancer. <i>Surgical Pathology Clinics</i> , 2021, 14, 387-401.	0.7	9

#	ARTICLE	IF	CITATIONS
338	Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Biomedicines</i> , 2021, 9, 1247.	1.4	22
339	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1250-1264.	5.1	159
340	Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity. <i>Cancer Research</i> , 2021, 81, 4901-4909.	0.4	6
341	Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives. <i>Cancer Letters</i> , 2021, 523, 162-169.	3.2	24
342	Associations between LncRNA MALAT1 Polymorphisms and Lymph Node Metastasis in Prostate Cancer. <i>Diagnostics</i> , 2021, 11, 1692.	1.3	10
343	Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4819-4832.	1.0	11
344	Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6164-6173.	3.2	10
345	Determinants of Homologous Recombination Deficiency in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4716.	1.7	9
346	Molecular Characterization of Prostate Cancers in the Precision Medicine Era. <i>Cancers</i> , 2021, 13, 4771.	1.7	10
347	Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?. <i>Anticancer Research</i> , 2021, 41, 4687-4695.	0.5	2
348	Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Targeted Oncology</i> , 2021, 16, 613-623.	1.7	6
349	Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA. <i>JAMA Oncology</i> , 2021, 7, 1378.	3.4	40
350	Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. <i>Clinical Cancer Research</i> , 2021, 27, 6106-6114.	3.2	9
351	Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 694363.	1.8	42
352	Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. <i>Cancers</i> , 2021, 13, 4522.	1.7	22
353	Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1-4.	1.1	1
354	Evaluating the Role of Stereotactic Body Radiation Therapy With Respect to Androgen Receptor Signaling Inhibitors for Oligometastatic Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2022, 7, 100808.	0.6	4
355	Are Homologous Recombination Deficiency Mutations Relevant in Colorectal Cancer?. <i>Journal of the National Cancer Institute</i> , 2022, 114, 176-178.	3.0	3

#	ARTICLE	IF	CITATIONS
356	Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 943-951.	2.0	9
357	A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss. <i>Frontiers in Oncology</i> , 2021, 11, 731002.	1.3	3
358	Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience. <i>JCO Precision Oncology</i> , 2021, 5, 1493-1506.	1.5	4
359	Kartogenin Inhibits Prostate Cancer Cell Growth Through Smad2 Activation and Decreases Androgen Receptor Nuclear Localization. <i>Anticancer Research</i> , 2021, 41, 4753-4759.	0.5	2
360	Gaps in Public Awareness About BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape Analysis. <i>JMIR Cancer</i> , 2021, 7, e27063.	0.9	10
361	25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 521-527.	0.8	3
362	PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. <i>Cancer Treatment Reviews</i> , 2021, 99, 102255.	3.4	25
363	Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9783.	1.8	35
364	Lutetium-177â€“PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 1091-1103.	13.9	1,042
365	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 271-279.	3.0	27
366	Talazoparib: a new biomarker-directed therapy in advanced prostate cancer. <i>Lancet Oncology</i> , The, 2021, 22, 1203-1204.	5.1	1
367	Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10319.	1.8	20
368	Recent Advances in the Management of Metastatic Prostate Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 45-55.	1.4	75
369	Prostate cancer. <i>Lancet</i> , The, 2021, 398, 1075-1090.	6.3	240
370	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline <i>ATM</i> versus <i>BRCA2</i> mutations. <i>Prostate</i> , 2021, 81, 1382-1389.	1.2	10
371	Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. <i>Cell Reports</i> , 2021, 36, 109665.	2.9	24
372	Comparison of the metabolome in urine prior and eight weeks after radical prostatectomy uncovers pathologic and molecular features of prostate cancer. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 205, 114288.	1.4	3
373	The treatment landscape of metastatic prostate cancer. <i>Cancer Letters</i> , 2021, 519, 20-29.	3.2	50

#	ARTICLE	IF	CITATIONS
374	Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study. <i>ESMO Open</i> , 2021, 6, 100241.	2.0	13
375	Asesoramiento genético en cáncer de próstata: ¿cómo implementarlo en la práctica clínica diaria?. <i>Actas Urológicas Españolas</i> , 2021, 45, 8-20.	0.3	2
376	Reduced survival of young patients under 55 years with metastatic prostate cancer: a population-based study. <i>Journal of Cancer</i> , 2021, 12, 4985-4992.	1.2	1
377	Prostate cancer: Therapeutic prospect with herbal medicine. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100034.	1.7	13
378	The role of PARP inhibitors in BRCA mutated pancreatic cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110148.	1.4	21
379	Upregulation of ATP Binding Cassette Subfamily C Member 5 facilitates Prostate Cancer progression and Enzalutamide resistance via the CDK1-mediated AR Ser81 Phosphorylation Pathway. <i>International Journal of Biological Sciences</i> , 2021, 17, 1613-1628.	2.6	10
380	DNA Damage Response. , 2021, , 1-12.		0
381	Genetic counseling in prostate cancer: How to implement it in daily clinical practice?. <i>Actas Urológicas Españolas (English Edition)</i> , 2021, 45, 8-20.	0.2	1
382	Molecular Subtyping and Precision Medicine for Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 149.	1.0	34
383	MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer. <i>Diagnostics</i> , 2021, 11, 84.	1.3	15
385	Olaparib for DNA repair-deficient prostate cancer – one for all, or all for one?. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 455-456.	12.5	6
388	Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097813.	1.4	11
389	First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.249029.	2.8	15
390	Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100480.	0.7	1
391	Guidelines for radiotherapy of prostate cancer (2020 edition). <i>Precision Radiation Oncology</i> , 2021, 5, 160-182.	0.4	8
393	Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View. <i>Cancers</i> , 2021, 13, 5216.	1.7	15
394	Genetics in prostate cancer: implications for clinical practice. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, 15, 241-246.	0.5	4
395	Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk. <i>Current Genetic Medicine Reports</i> , 2021, 9, 47-58.	1.9	5

#	ARTICLE	IF	CITATIONS
396	Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. <i>European Urology</i> , 2022, 81, 559-567.	0.9	17
397	Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction. <i>Frontiers in Oncology</i> , 2021, 11, 675972.	1.3	21
398	Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 61-81.	0.7	5
399	The prevalence and clinical implication of rare germline deleterious alterations in Chinese patients with prostate cancer: A real-world multicenter study. <i>Clinical and Translational Medicine</i> , 2021, 11, e527.	1.7	2
400	Harnessing multimodal data integration to advance precision oncology. <i>Nature Reviews Cancer</i> , 2022, 22, 114-126.	12.8	168
401	Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications. <i>Cancers</i> , 2021, 13, 5257.	1.7	22
402	3-O-Carbamoyl-5,7,20-O-trimethylsilybins: Synthesis and Preliminary Antiproliferative Evaluation. <i>Molecules</i> , 2021, 26, 6421.	1.7	1
403	Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 109-126.	0.6	9
404	Setting a diagnostic benchmark for tumor BRCA testing: detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue – A pilot study. <i>Experimental and Molecular Pathology</i> , 2021, 123, 104705.	0.9	1
405	Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 1721-1731.	5.1	172
406	Application of extracellular vesicles in the diagnosis and treatment of prostate cancer: implications for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103495.	2.0	11
407	PARP inhibitors: clinical relevance and the role of multidisciplinary cancer teams on drug safety. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 541-551.	1.0	2
408	Acknowledging Disparities in Hereditary Cancer Testing. <i>Journal of Clinical Oncology</i> , 2021, 39, 4001-4003.	0.8	2
410	Prostatakarzinom: Die optimale Sequenz für die zweite und nachfolgende Therapielinien beim mCRPC ist noch nicht gefunden. <i>Karger Kompass Onkologie</i> , 2020, 7, 197-198.	0.0	0
412	Leveraging Veterans Health Administration Clinical and Research Resources to Accelerate Discovery and Testing in Precision Oncology. , 2020, 37, S62-S67.		0
413	The Precision Oncology Program for Cancer of the Prostate (POPCaP) Network: A Veterans Affairs/Prostate Cancer Foundation Collaboration. , 2020, 37, S48-S53.		0
415	KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients. <i>Translational Andrology and Urology</i> , 2021, 10, 3946-3952.	0.6	5
416	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. <i>Cancers</i> , 2021, 13, 5415.	1.7	13

#	ARTICLE	IF	CITATIONS
417	BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2021, 11, 718871.	1.3	6
418	Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0
419	Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era. <i>Cancer Medicine</i> , 2021, 10, 7909-7920.	1.3	2
420	Identification of DNA Damage Repair-Associated Prognostic Biomarkers for Prostate Cancer Using Transcriptomic Data Analysis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11771.	1.8	6
421	Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1584-1594.	3.3	24
423	Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort. <i>PLoS ONE</i> , 2020, 15, e0244149.	1.1	4
425	Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1792-1806.	3.2	13
426	Anticipating the Next Challenging Clinical Dilemmas in Prostate Cancer. <i>JCO Oncology Practice</i> , 2020, 16, 791-792.	1.4	0
427	Experimental challenges to modeling prostate cancer heterogeneity. <i>Cancer Letters</i> , 2022, 524, 194-205.	3.2	11
428	History of Oncotherapies in Cancer Biology. , 2020, , 1-13.		1
429	PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations. <i>JCO Precision Oncology</i> , 2021, 5, 1639-1649.	1.5	7
430	Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting. <i>Prostate</i> , 2021, , .	1.2	2
431	Predictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine. <i>JCO Precision Oncology</i> , 2021, 5, 1699-1708.	1.5	10
432	Implementation of a molecular tumour board in LATAM: the impact on treatment decisions for patients evaluated at Instituto Alexander Fleming, Argentina. <i>Ecancermedicalsecience</i> , 2021, 15, 1312.	0.6	3
433	Leveraging Real World Genomic Data to Advance Prostate Cancer Precision Oncology. <i>European Urology</i> , 2022, 81, 48-49.	0.9	1
434	Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology. <i>Pharmacogenomics</i> , 2021, 22, 1237-1250.	0.6	1
435	Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score. <i>Clinical Cancer Research</i> , 2022, 28, 1412-1421.	3.2	46
436	Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects. <i>European Journal of Cancer</i> , 2021, 159, 87-97.	1.3	6

#	ARTICLE	IF	CITATIONS
438	Immunotherapy and Novel Agents on the Horizon for the Treatment of Prostate Cancer. , 2021, , 133-138.		0
442	Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations. American Journal of Translational Research (discontinued), 2021, 13, 7427-7439.	0.0	1
443	Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer-a narrative review. Translational Andrology and Urology, 2021, 10, 3188-3198.	0.6	1
444	Molecular signatures of aggressive pediatric liver cancer. , 2021, 2, 1-4.		0
445	Genomic alterations in tumor tissue and ctDNA from Chinese pancreatic cancer patients. American Journal of Cancer Research, 2021, 11, 4551-4567.	1.4	1
446	Genetics of prostate cancer and its utility in treatment and screening. Advances in Genetics, 2021, 108, 147-199.	0.8	3
447	PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls. Translational Oncology, 2022, 15, 101263.	1.7	2
448	Prostatakarzinom. , 2022, , 314-327.		0
449	Molecular tests for prediction of tumor sensitivity to cytotoxic drugs. Cancer Letters, 2022, 526, 41-52.	3.2	9
450	Inherited Mutations in Chinese Men With Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 54-62.	2.3	13
452	BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations. International Journal of Molecular Sciences, 2021, 22, 12628.	1.8	44
453	Germinal & BRCA-mutation significance in the tumor microenvironment formation Efficacy of PARP inhibition in late-line therapy of metastatic castration-resistant prostate cancer. Onkourologiya, 2021, 17, 85-94.	0.1	2
454	Biomarkers for Treatment Response in Advanced Prostate Cancer. Cancers, 2021, 13, 5723.	1.7	14
455	Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer. Cancers, 2021, 13, 5697.	1.7	10
456	Clinical and genomic features of SPOP-mutant prostate cancer. Prostate, 2022, 82, 260-268.	1.2	20
457	Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice. Clinical Genitourinary Cancer, 2022, 20, e104-e113.	0.9	7
458	An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer. International Journal of General Medicine, 2021, Volume 14, 9031-9049.	0.8	0
459	Exploring the Value of BRD9 as a Biomarker, Therapeutic Target and Co-Target in Prostate Cancer. Biomolecules, 2021, 11, 1794.	1.8	4

#	ARTICLE	IF	CITATIONS
460	Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. <i>Cancers</i> , 2021, 13, 5847.	1.7	16
461	Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	2
462	CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12777.	1.8	16
464	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. <i>European Journal of Cancer</i> , 2022, 160, 24-60.	1.3	12
465	Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 5830.	1.7	19
466	DNA Damage Response. , 2021, , 536-547.		0
468	Racial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview. <i>World Journal of Men's Health</i> , 2022, 40, 217.	1.7	19
469	Analysis of the Role of Comprehensive Treatment Model in the Treatment of Prostate Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-7.	0.7	1
470	Biomarker-driven immunotherapy for precision medicine in prostate cancer. <i>Personalized Medicine</i> , 2022, 19, 51-66.	0.8	1
471	Genetic Analysis Reveals the Prognostic Significance of the DNA Mismatch Repair Gene MSH2 in Advanced Prostate Cancer. <i>Cancers</i> , 2022, 14, 223.	1.7	5
472	Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. <i>Oncologist</i> , 2022, 27, 220-227.	1.9	5
473	The emerging roles of NGS in clinical oncology and personalized medicine. <i>Pathology Research and Practice</i> , 2022, 230, 153760.	1.0	25
474	Olaparib-Induced Immune-Mediated Liver Injury. <i>ACG Case Reports Journal</i> , 2022, 9, e00735.	0.2	1
476	Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. <i>Journal of Personalized Medicine</i> , 2022, 12, 72.	1.1	26
477	The prostate cancer landscape in Europe: Current challenges, future opportunities. <i>Cancer Letters</i> , 2022, 526, 304-310.	3.2	16
478	Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities. <i>European Journal of Medicinal Chemistry</i> , 2022, 230, 114094.	2.6	18
479	RNA Sequencing Provides Evidence for Pathogenicity of a Novel <i>CHEK2</i> Splice Variant (C.1009-7T>G). <i>Annals of Laboratory Medicine</i> , 2022, 42, 380-383.	1.2	2
480	Nuclear medicine therapy of prostate cancer: State of the art and future perspectives. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
481	Management of Metastatic Castration-Resistant Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 614-616.	2.3	0
482	Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3188-3198.	0.6	3
483	PARP Inhibitors in Pancreatic Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 465-475.	1.0	18
484	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13519.	1.8	13
485	Prostate cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 577-590.	1.4	17
486	Personalized 3-Gene Panel for Prostate Cancer Target Therapy. <i>Current Issues in Molecular Biology</i> , 2022, 44, 360-382.	1.0	5
487	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes. <i>Biomedicines</i> , 2022, 10, 236.	1.4	13
488	PROFOUND trial—a new era in targeted therapeutics for prostate carcinoma. <i>Indian Journal of Urology</i> , 2022, 38, 73.	0.2	1
489	Olaparib-Induced Senescence Is Bypassed through G2/M Checkpoint Override in Olaparib-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 677-685.	1.9	6
490	Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion. <i>Cancer Biology and Therapy</i> , 2022, 23, 69-82.	1.5	3
491	The Development of ¹⁸ F Fluorothantrate: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1. <i>Radiology Imaging Cancer</i> , 2022, 4, e210070.	0.7	3
492	Transcriptome subtyping of metastatic Castration Resistance Prostate Cancer (mCRPC) for the precision therapeutics: an in silico analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 327-335.	2.0	5
493	ATM: Functions of ATM Kinase and Its Relevance to Hereditary Tumors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 523.	1.8	18
495	Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 67-73.	2.0	2
496	Rational Second-Generation Antiandrogen Use in Prostate Cancer. <i>Oncologist</i> , 0, , .	1.9	10
497	Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?. <i>Cancers</i> , 2022, 14, 440.	1.7	20
498	DNA damage response inhibitor and anti-PD-L1 therapy for prostate cancer: Development of predictive biomarkers. <i>Engineering</i> , 2022, , .	3.2	0
499	Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 642-649.	0.7	4

#	ARTICLE	IF	CITATIONS
500	Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. <i>Cancers</i> , 2022, 14, 503.	1.7	21
501	Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). <i>Clinical Cancer Research</i> , 2022, 28, 1518-1530.	3.2	41
502	Characterization of the Genomic Landscape in Cervical Cancer by Next Generation Sequencing. <i>Genes</i> , 2022, 13, 287.	1.0	8
503	Differential Gene Expression Profiles between N-Terminal Domain and Ligand-Binding Domain Inhibitors of Androgen Receptor Reveal Ralaniten Induction of Metallothionein by a Mechanism Dependent on MTF1. <i>Cancers</i> , 2022, 14, 386.	1.7	4
504	Harnessing Synthetic Lethal Interactions for Personalized Medicine. <i>Journal of Personalized Medicine</i> , 2022, 12, 98.	1.1	6
505	Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer. <i>Cancers</i> , 2022, 14, 407.	1.7	5
506	Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?. <i>Frontiers in Oncology</i> , 2021, 11, 778761.	1.3	8
507	Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 441-448.	0.6	9
508	Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan. <i>Future Oncology</i> , 2022, 18, 937-951.	1.1	11
509	A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2022, 18, 1185-1198.	1.1	10
510	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 761-770.	3.0	3
511	Mutation Landscape of Homologous Recombination Repair Genes in Epithelial Ovarian Cancer in China and Its Relationship With Clinicopathological Characteristics. <i>Frontiers in Oncology</i> , 2022, 12, 709645.	1.3	4
512	Advances with androgen deprivation therapy for prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1015-1033.	0.9	10
513	Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. <i>Future Oncology</i> , 2022, 18, 425-436.	1.1	28
514	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology. <i>Cancer Treatment Reviews</i> , 2022, 104, 102337.	3.4	6
515	Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer—Where Are We Now?. <i>Cancers</i> , 2022, 14, 801.	1.7	23
516	Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 314-319.	2.0	6
518	Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 362-373.	5.1	97

#	ARTICLE	IF	CITATIONS
519	Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 393-405.	5.1	16
521	Clinical Utility of Liquid Biopsy to Identify Genomic Heterogeneity and Secondary Cancer Diagnoses: A Case Report. <i>Case Reports in Oncology</i> , 2022, 15, 78-85.	0.3	0
522	PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence. <i>Cancer Treatment Reviews</i> , 2022, 104, 102359.	3.4	9
523	Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy. <i>Frontiers in Immunology</i> , 2022, 13, 826577.	2.2	3
524	Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103539.	2.0	11
525	PET imaging of prostate cancer. , 2022, , .		0
526	Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210830.	1.4	11
527	Germline alterations among Hispanic men with prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 561-567.	2.0	4
528	RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 185-199.	1.5	16
529	PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming?. <i>Cancers</i> , 2022, 14, 907.	1.7	8
530	Genetic medicine is accelerating in Japan. <i>Breast Cancer</i> , 2022, 29, 659-665.	1.3	5
532	PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. <i>Cancers</i> , 2022, 14, 1003.	1.7	18
533	Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents. <i>Cancers</i> , 2022, 14, 953.	1.7	16
534	Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer. <i>Cancers</i> , 2022, 14, 1133.	1.7	6
535	Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Management and Research</i> , 2022, Volume 14, 673-686.	0.9	4
536	Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number. <i>Biology Direct</i> , 2022, 17, 5.	1.9	1
537	Immunotherapy in Advanced Prostate Cancer—Light at the End of the Tunnel?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2569.	1.8	11
538	Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2571.	1.8	8

#	ARTICLE	IF	CITATIONS
539	The Feasibility of Implementing Mainstream Germline Genetic Testing in Routine Cancer Care—A Systematic Review. <i>Cancers</i> , 2022, 14, 1059.	1.7	30
540	Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?. <i>Journal of Clinical Oncology</i> , 2022, 40, 1518-1521.	0.8	9
541	Genetic testing in prostate cancer management: Considerations informing primary care. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 360-371.	157.7	15
543	Exploring the Wnt Pathway as a Therapeutic Target for Prostate Cancer. <i>Biomolecules</i> , 2022, 12, 309.	1.8	14
544	Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation. <i>BMC Medical Genomics</i> , 2022, 15, 32.	0.7	2
545	Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 137-141.	0.6	0
546	Implications of DNA damage repair alterations for the management of prostate cancer. <i>Current Opinion in Urology</i> , 2022, 32, 302-310.	0.9	1
547	Immune mechanisms behind prostate cancer in men of African ancestry: A review. <i>Prostate</i> , 2022, 82, 883-893.	1.2	1
548	Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review. <i>Cancers</i> , 2022, 14, 1792.	1.7	15
549	Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC. <i>Cancers</i> , 2022, 14, 1696.	1.7	10
550	Pan-cancer analysis identifies LMNB1 as a target to redress Th1/Th2 imbalance and enhance PARP inhibitor response in human cancers. <i>Cancer Cell International</i> , 2022, 22, 101.	1.8	7
551	Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy. <i>Anticancer Research</i> , 2022, 42, 2123-2130.	0.5	3
552	Signaling Pathways and Targeted Therapies for Stem Cells in Prostate Cancer. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 193-206.	2.5	8
553	Clinical trials for metastatic castrate-resistant prostate cancer—“who is looking after the control patients? Questions for the future. <i>Annals of Oncology</i> , 2022, 33, 574-577.	0.6	4
554	A clinician’s handbook for using ctDNA throughout the patient journey. <i>Molecular Cancer</i> , 2022, 21, 81.	7.9	43
555	A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer. <i>Molecular Cancer</i> , 2022, 21, 82.	7.9	6
557	Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes. <i>Nature Communications</i> , 2022, 13, 1361.	5.8	8
558	Prostate cancer treatment costs increase more rapidly than for any other cancer—“how to reverse the trend?. <i>EPMA Journal</i> , 2022, 13, 1-7.	3.3	26

#	ARTICLE	IF	CITATIONS
559	Clinical and analytical validation of FoundationOne [®] CDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE, 2022, 17, e0264138.	1.1	100
560	Targeting radioresistance and replication fork stability in prostate cancer. JCI Insight, 2022, 7, .	2.3	4
561	Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS. Frontiers in Pharmacology, 2022, 13, 851246.	1.6	15
562	Identification of a Steroid Hormone-Associated Gene Signature Predicting the Prognosis of Prostate Cancer through an Integrative Bioinformatics Analysis. Cancers, 2022, 14, 1565.	1.7	4
563	The role of genetic testing in prostate cancer screening, diagnosis, and treatment. Current Opinion in Oncology, 2022, Publish Ahead of Print, .	1.1	0
564	PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. Journal of Clinical Medicine, 2022, 11, 1734.	1.0	5
565	PARP Inhibitors Resistance: Mechanisms and Perspectives. Cancers, 2022, 14, 1420.	1.7	22
566	Peroxisome Proliferator-activated Receptor Gamma Coactivator-1 Alpha: A Double-edged Sword in Prostate Cancer. Current Cancer Drug Targets, 2022, 22, 541-559.	0.8	7
567	PARP inhibition in breast cancer: progress made and future hopes. Npj Breast Cancer, 2022, 8, 47.	2.3	42
568	The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide. BMC Cancer, 2022, 22, 375.	1.1	0
569	Recent Advances in Medical Therapy for Urological Cancers. Frontiers in Oncology, 2022, 12, 746922.	1.3	8
570	A phase I study of talazoparib (<sc>BMN</sc> 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (<sc>NCI9782</sc>). Cancer Medicine, 2022, 11, 3969-3981.	1.3	11
571	Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2022, 28, 2237-2247.	3.2	16
572	Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report. World Journal of Clinical Cases, 2022, 10, 3461-3471.	0.3	2
573	Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. European Journal of Cancer, 2022, 166, 87-99.	1.3	21
574	Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors. Cancer Journal (Sudbury, Mass), 2021, 27, 482-490.	1.0	0
575	Development of Next-Generation Poly(ADP-Ribose) Polymerase 1 st Selective Inhibitors. Cancer Journal (Sudbury, Mass), 2021, 27, 521-528.	1.0	10
576	PARP Inhibition in Advanced Prostate Cancer. Cancer Journal (Sudbury, Mass), 2021, 27, 457-464.	1.0	3

#	ARTICLE	IF	CITATIONS
578	Analysis of <i>CDK12</i> alterations in a pan-cancer database. <i>Cancer Medicine</i> , 2022, 11, 753-763.	1.3	6
579	Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. <i>Clinical Breast Cancer</i> , 2021, , .	1.1	6
580	Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	15
581	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. <i>Cancers</i> , 2021, 13, 6385.	1.7	19
582	Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape. <i>Cancers</i> , 2022, 14, 44.	1.7	16
583	Practice-changing Clinical Studies in Prostate Cancer: an Update for the Medical Oncologist. <i>Journal of Medical & Radiation Oncology</i> , 2021, 1, 27-34.	0.0	0
584	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer—Current State and Future Perspectives. <i>Cancers</i> , 2022, 14, 147.	1.7	2
585	Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 60-78.	1.0	5
586	PARP inhibitors as a radiosensitizer: a future promising approach in prostate cancer?. <i>Ecancermedalscience</i> , 2021, 15, ed118.	0.6	4
588	Case Report: Combination of Olaparib With Chemotherapy in a Patient With ATM-Deficient Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 788809.	1.3	9
589	Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. <i>British Journal of Cancer</i> , 2022, 126, 907-916.	2.9	5
591	Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13125.	1.8	6
592	Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 3133-3140.	0.6	2
593	PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 607-631.	1.9	20
595	Rucaparib and olaparib for the treatment of prostate cancer: A clinician's guide to choice of therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1624-1633.	0.5	4
596	Germline testing and genetic counselling in prostate cancer. <i>Nature Reviews Urology</i> , 2022, 19, 331-343.	1.9	18
597	Expansion of Cancer Risk Profile for <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2022, 8, 871.	3.4	70
598	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	0.9	51

#	ARTICLE	IF	CITATIONS
599	The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 431-443.	2.0	44
601	A Phenome-Wide Association Study and the Discovery of a New Clinical Spectrum of Hereditary Cancer Genes. <i>JAMA Oncology</i> , 2022, , .	3.4	1
602	<i>RB1</i> loss overrides PARP inhibitor sensitivity driven by <i>RNASEH2B</i> loss in prostate cancer. <i>Science Advances</i> , 2022, 8, eabl9794.	4.7	14
603	Rapid Response of a <i>BRCA2/TP53/PTEN</i> -Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report. , 2021, 25, 1-1.		9
605	Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2022, 13, 2226-2237.	1.2	2
606	Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4709.	1.8	13
607	Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives. <i>Medical Sciences (Basel, Switzerland)</i> , 2022, 10, 25.	1.3	10
608	Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-51.	0.7	4
609	Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment. <i>Cells</i> , 2022, 11, 1466.	1.8	6
610	DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. <i>Cells</i> , 2022, 11, 1463.	1.8	3
612	Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
613	Identification of Neoantigens and Construction of Immune Subtypes in Prostate Adenocarcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 886983.	1.1	0
615	Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cell-derived explants. <i>JCI Insight</i> , 2022, , .	2.3	5
616	PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer. <i>Drugs</i> , 2022, 82, 719-733.	4.9	10
617	Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial. <i>Cancers</i> , 2022, 14, 2275.	1.7	0
618	Deoxyribonucleic Acid Damage Response Defects. <i>Advances in Oncology</i> , 2022, 2, 195-211.	0.1	0
619	Alterations in homologous recombination repair genes in prostate cancer brain metastases. <i>Nature Communications</i> , 2022, 13, 2400.	5.8	13
620	Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland. <i>Prostate International</i> , 2022, 10, 142-147.	1.2	4

#	ARTICLE	IF	CITATIONS
621	FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint. <i>Journal of Personalized Medicine</i> , 2022, 12, 750.	1.1	13
622	Establishment of a Novel Combined Nomogram for Predicting the Risk of Progression Related to Castration Resistance in Patients With Prostate Cancer. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	4
624	Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1115-1124.	1.9	3
625	The lactate-NAD ⁺ axis activates cancer-associated fibroblasts by downregulating p62. <i>Cell Reports</i> , 2022, 39, 110792.	2.9	22
626	The role of chemotherapy in metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2022, 32, 292-301.	0.9	4
627	Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management. <i>Current Opinion in Urology</i> , 2022, 32, 283-291.	0.9	4
628	Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 235-240.	1.5	6
629	Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology. <i>Endocrinology</i> , 2022, 163, .	1.4	21
630	Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3127-3140.	3.2	11
631	Precision intervention for prostate cancer: Re-evaluating who is at risk. <i>Cancer Letters</i> , 2022, 538, 215709.	3.2	9
633	Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. <i>Current Oncology Reports</i> , 2022, 24, 1287-1298.	1.8	4
634	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. <i>Cancers</i> , 2022, 14, 2470.	1.7	4
635	Metronomic Chemotherapy in Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 2853.	1.0	6
636	Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 97-104.	1.1	2
637	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459.	2.0	26
638	Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. <i>European Journal of Cancer</i> , 2022, 170, 73-84.	1.3	10
639	Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 366-382.	1.8	12
640	Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. <i>NAR Cancer</i> , 2022, 4, .	1.6	4

#	ARTICLE	IF	CITATIONS
641	Current Trends in Advanced Prostate Cancer Medical Setting. Proceedings of the Latvian Academy of Sciences, 2022, 76, 168-180.	0.0	0
642	Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis. Medical Oncology, 2022, 39, .	1.2	4
643	Molecular mechanisms underlying the development of neuroendocrine prostate cancer. Seminars in Cancer Biology, 2022, 86, 57-68.	4.3	17
644	Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort. BMC Cancer, 2022, 22, .	1.1	18
645	Clinical implications of homologous recombination repair mutations in prostate cancer. Prostate, 2022, 82, .	1.2	4
646	Germline genetics of prostate cancer. Prostate, 2022, 82, .	1.2	8
647	Nanomedicine for urologic cancers: diagnosis and management. Seminars in Cancer Biology, 2022, 86, 463-475.	4.3	3
648	Prostate Cancer Treatment: ¹⁷⁷ Lu-PSMA-617 Considerations, Concepts, and Limitations. Journal of Nuclear Medicine, 2022, 63, 823-829.	2.8	6
649	Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors. Cancers, 2022, 14, 2804.	1.7	5
650	Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer. Prostate, 2022, 82, .	1.2	6
651	Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2022, 1, .		124
652	Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate, 2022, 82, .	1.2	3
653	PSMA theragnostics for metastatic castration resistant prostate cancer. Translational Oncology, 2022, 22, 101438.	1.7	5
655	Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 667-90.	0.9	8
656	Genomics of Breast Cancer Brain Metastases: A Meta-Analysis and Therapeutic Implications. SSRN Electronic Journal, 0, , .	0.4	0
658	Molecular analysis of ascitic fluid cytology reflects genetic changes of malignancies of the ovary equivalent to surgically resected specimens. Cancer Cytopathology, 2022, 130, 640-649.	1.4	5
659	Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing. JCO Precision Oncology, 2022, , .	1.5	7
660	Poster Session 9: Oncology â€“ Prostate. Canadian Urological Association Journal, 2022, 16, .	0.3	0

#	ARTICLE	IF	CITATIONS
661	Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada. Canadian Urological Association Journal, 2022, 16, .	0.3	3
662	Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumour-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer. Journal of Drug Targeting, 0, , 1-18.	2.1	7
663	Chemotherapy Regimens Received by Women with <i>BRCA1/2</i> Pathogenic Variants for Early-Stage Breast Cancer Treatment. JNCI Cancer Spectrum, 0, , .	1.4	0
664	Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified <sc>ALCAM</sc> as marker of resistance in castration-resistant prostate cancer. International Journal of Cancer, 0, , .	2.3	3
665	Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD). Npj Precision Oncology, 2022, 6, .	2.3	23
666	PARP Inhibitors: A New Horizon for Patients with Prostate Cancer. Biomedicines, 2022, 10, 1416.	1.4	20
667	Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations. Expert Review of Anticancer Therapy, 2022, 22, 717-723.	1.1	1
668	Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275)., 2022, 39, .		2
669	Pilot Study: PARP1 Imaging in Advanced Prostate Cancer. Molecular Imaging and Biology, 2022, 24, 853-861.	1.3	3
670	A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report. BMC Medical Genomics, 2022, 15, .	0.7	1
671	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	40
672	Validation of a Patient-Derived Xenograft Model for Cervical Cancer Based on Genomic and Phenotypic Characterization. Cancers, 2022, 14, 2969.	1.7	4
673	Technology-enhanced Acceleration of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Contemporary Clinical Trials, 2022, 119, 106821.	0.8	4
674	Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). Journal of Clinical Oncology, 2023, 41, 43-53.	0.8	24
675	Metformin Can Enhance the Inhibitory Effect of Olaparib in Bladder Cancer Cells. Disease Markers, 2022, 2022, 1-10.	0.6	2
676	The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. Cancers, 2022, 14, 2950.	1.7	9
677	Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. British Journal of Cancer, 2022, 127, 1394-1402.	2.9	25
678	Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. Breast, 2022, 65, 32-40.	0.9	25

#	ARTICLE	IF	CITATIONS
679	An appraisal of genetic testing for prostate cancer susceptibility. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	6
680	RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. <i>JCO Precision Oncology</i> , 2022, , .	1.5	1
681	A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration. <i>Current Oncology</i> , 2022, 29, 4178-4184.	0.9	1
683	PARP Inhibitor Insensitivity to <i>BRCA1/2</i> Monoallelic Mutations in Microsatellite Instability-High Cancers. <i>JCO Precision Oncology</i> , 2022, , .	1.5	15
684	Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer. <i>Cancers</i> , 2022, 14, 3175.	1.7	6
685	The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 515-523.	0.9	4
686	A case of metastatic treatmentâ€emergent small cell/neuroendocrine prostate cancer with <i>BRCA2</i> mutation diagnosed by liver biopsy. <i>IJU Case Reports</i> , 2022, 5, 431-435.	0.1	5
688	Therapeutic targets and signaling pathways of active components of QiLing decoction against castration-resistant prostate cancer based on network pharmacology. <i>PeerJ</i> , 0, 10, e13481.	0.9	0
689	Treatment-Refractory, Castration-Resistant Prostate Cancer With Liver Metastasis: A Promising Modality of Therapy. <i>Cureus</i> , 2022, , .	0.2	0
690	Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice. Observational study. <i>Journal of Modern Oncology</i> , 2022, 24, 221-225.	0.1	0
691	Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice. , 2022, 39, .		5
693	<i>BRCA2</i> Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series. <i>JCO Precision Oncology</i> , 2022, , .	1.5	6
694	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2022, 33, 750-768.	0.6	204
695	Reconsidering the mechanisms of action of <i>PARP</i> inhibitors based on clinical outcomes. <i>Cancer Science</i> , 2022, 113, 2943-2951.	1.7	11
696	Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations. <i>Current Opinion in Oncology</i> , 2022, 34, 559-569.	1.1	6
697	Synergistic Benefit of Adoptive T Cells in Combination With Chemoradiotherapy Against Metastatic Prostate Cancer Cells. <i>Anticancer Research</i> , 2022, 42, 3427-3434.	0.5	0
698	Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7481.	1.8	12
699	Multisite Radiotherapy Combined With Tiselizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1

#	ARTICLE	IF	CITATIONS
700	Role of ubiquitin specific proteases in the immune microenvironment of prostate cancer: A new direction. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
701	Understanding the Current Therapeutic Landscape for Advanced Prostate Cancer (CME article). <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, .	0.0	0
702	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. <i>JCO Precision Oncology</i> , 2022, , .	1.5	10
703	Current status and future perspective on the management of metastatic castration-sensitive prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100606.	0.7	4
704	A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
705	2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial. <i>Acta OncolÁgica</i> , 2022, 61, 963-971.	0.8	1
706	Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
707	Review of Toxicities of PARP Inhibitors in Metastatic Castrate Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 183-193.	0.9	6
708	The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. <i>Scandinavian Journal of Urology</i> , 2022, 56, 278-284.	0.6	10
709	Emerging Biomarker-Guided Therapies in Prostate Cancer. <i>Current Oncology</i> , 2022, 29, 5054-5076.	0.9	10
710	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. <i>ESMO Open</i> , 2022, 7, 100518.	2.0	10
711	Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021. <i>European Journal of Cancer</i> , 2022, 172, 349-356.	1.3	0
712	Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib. <i>Journal of Immunology Research</i> , 2022, 2022, 1-11.	0.9	1
713	Geospatial Immune Heterogeneity Reflects the Diverse Tumorâ€Immune Interactions in Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 2350-2371.	7.7	28
714	Challenges in next generation sequencing of homology recombination repair genomic variants in prostate cancer: A nationwide survey and calibration project in China. <i>Prostate International</i> , 2022, 10, 181-187.	1.2	1
715	Opinion: PARP inhibitors in cancerâ€what do we still need to know?. <i>Open Biology</i> , 2022, 12, .	1.5	10
716	Oleocanthal Attenuates Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence by Targeting SMYD2. <i>Cancers</i> , 2022, 14, 3542.	1.7	5
717	Molecular uropathology and cancer genetics for the urologist: key findings for classification and diagnosis. <i>Current Opinion in Urology</i> , 2022, 32, 451-455.	0.9	2

#	ARTICLE	IF	CITATIONS
718	Potential Ophthalmological Side Effects Induced by Anti-Neoplastic Regimens for the Treatment of Genitourinary Cancers: A Review. <i>Cureus</i> , 2022, , .	0.2	0
719	IKK μ Inhibitor Amlexanox Promotes Olaparib Sensitivity through the C/EBP- β -Mediated Transcription of Rad51 in Castrate-Resistant Prostate Cancer. <i>Cancers</i> , 2022, 14, 3684.	1.7	1
721	Editorial Comment from Dr Kato to A case of metastatic treatment-€emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation by liver biopsy. <i>IJU Case Reports</i> , 2022, 5, 436-437.	0.1	1
722	Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic. <i>American Journal of Men's Health</i> , 2022, 16, 155798832211155.	0.7	1
724	Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance. <i>Cancers</i> , 2022, 14, 3877.	1.7	3
725	Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer. <i>World Journal of Urology</i> , 2023, 41, 2021-2031.	1.2	3
726	The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8535.	1.8	9
727	Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization. <i>Nuclear Medicine and Molecular Imaging</i> , 2022, 56, 263-281.	0.6	4
728	A patient-driven clinicogenomic partnership for metastatic prostate cancer. <i>Cell Genomics</i> , 2022, 2, 100169.	3.0	4
729	Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer. <i>Current Oncology Reports</i> , 0, , .	1.8	4
730	What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
731	Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease. <i>Biomedicines</i> , 2022, 10, 1872.	1.4	6
732	A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer. <i>Oncogene</i> , 2022, 41, 4271-4281.	2.6	9
733	Patterns of structural variation define prostate cancer across disease states. <i>JCI Insight</i> , 2022, 7, .	2.3	3
734	Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers. <i>Annals of Oncology</i> , 2022, 33, 1186-1199.	0.6	21
737	Wnt/ β -Catenin-Pathway Alterations and Homologous Recombination Deficiency in Cholangiocarcinoma Cell Lines and Clinical Samples: Towards Specific Vulnerabilities. <i>Journal of Personalized Medicine</i> , 2022, 12, 1270.	1.1	2
738	Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. , 2022, 10, e004761.		15
739	BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. <i>Cancers</i> , 2022, 14, 3888.	1.7	56

#	ARTICLE	IF	CITATIONS
740	Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician's Perspective. <i>Cancer Management and Research</i> , 0, Volume 14, 2389-2397.	0.9	0
741	Seleno-Aspirin compound AS10 promotes histone acetylation ahead of suppressing androgen receptor transcription, G1 arrest, and apoptosis of prostate cancer cells. <i>Prostate</i> , 0, .	1.2	2
742	Discordant Endorsement of Prostate Cancer Biomarkers Across Major Guidelines. <i>European Urology Focus</i> , 2022, 8, 919-921.	1.6	2
743	Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board. <i>Oncologist</i> , 2023, 28, 33-39.	1.9	2
744	Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience. <i>PLoS ONE</i> , 2022, 17, e0264800.	1.1	1
746	DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies. <i>European Surgical Research</i> , 2022, 63, 155-164.	0.6	8
747	Factors influencing survival in metastatic castration-resistant prostate cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1061-1079.	1.1	2
748	Resistance to prostate cancer treatments. <i>IUBMB Life</i> , 2023, 75, 390-410.	1.5	4
749	Should We "PROpel" Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?. , 2022, 1, .		0
750	m6A Methylation Regulators Are Predictive Biomarkers for Tumour Metastasis in Prostate Cancer. <i>Cancers</i> , 2022, 14, 4035.	1.7	5
751	Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States. <i>Annals of Translational Medicine</i> , 2022, 10, 830-830.	0.7	4
752	Upregulation of PARG in prostate cancer cells suppresses their malignant behavior and downregulates tumor-promoting genes. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113504.	2.5	2
753	<sc>miRNAs</sc> in prostate cancer: Intercellular and extracellular communications. <i>International Journal of Urology</i> , 2022, 29, 1429-1438.	0.5	6
754	Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens. <i>Oncologist</i> , 2022, 27, e970-e972.	1.9	3
755	Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. <i>Prostate Cancer and Prostatic Diseases</i> , 0, , .	2.0	0
756	Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1297-1307.	5.1	12
757	Nanoparticle-based Olaparib delivery enhances its effect, and improves drug sensitivity to cisplatin in triple negative breast cancer. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103731.	1.4	1
758	Comparison of Homologous Recombination Repair Gene Next-Generation Sequencing Analysis in Patients With Metastatic Castration-Resistant Prostate Cancer Between Local and Central Laboratories in Korea. <i>Annals of Laboratory Medicine</i> , 2023, 43, 64-72.	1.2	1

#	ARTICLE	IF	CITATIONS
759	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1-55.		0
760	DNA damage, metabolism, and epigenetic regulation. , 2022, , 111-138.		0
761	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1023-1075.		0
762	PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC?. Indian Journal of Urology, 2022, 38, 319.	0.2	0
764	VRK1 as a synthetic lethal target in VRK2 promoterâ€“methylated cancers of the nervous system. JCI Insight, 2022, 7, .	2.3	10
765	Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race. Oncologist, 2022, 27, e815-e818.	1.9	2
766	Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. JCO Precision Oncology, 2022, , .	1.5	2
767	Detection of <i>BRCA1</i> , <i>BRCA2</i> , and <i>ATM</i> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clinical Cancer Research, 2023, 29, 81-91.	3.2	19
768	Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset. Life, 2022, 12, 1355.	1.1	2
769	Precision Medicine for Prostate Cancer Based on Genetic Mutation. Journal of the Nihon University Medical Association, 2022, 81, 187-192.	0.0	0
770	Genomic Landscape Alterations in Primary Tumor and Matched Lymph Node Metastasis in Hormone-Naïve Prostate Cancer Patients. Cancers, 2022, 14, 4212.	1.7	3
771	Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. European Urology, 2023, 83, 15-26.	0.9	22
772	Drugâ€“gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition. Cancer Research Communications, 2022, 2, 1244-1254.	0.7	7
774	Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. Clinical Cancer Research, 2022, 28, 4714-4723.	3.2	15
775	PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures. Cancers, 2022, 14, 4751.	1.7	4
776	Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients. Cancers, 2022, 14, 4447.	1.7	5
777	Efficacy of cabazitaxel in patients with metastatic castrationâ€“resistant prostate cancer: A singleâ€“center study in Japan. International Journal of Urology, 0, , .	0.5	0
779	Chronological Liquid Biopsy Reveals the Impact of Platinum-Based Chemotherapy on a Prostate Cancer Patientâ€™s CDK12 Mutation: A Case Report. OncoTargets and Therapy, 0, Volume 15, 947-952.	1.0	2

#	ARTICLE	IF	CITATIONS
780	Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer. <i>European Urology</i> , 2023, 83, 29-38.	0.9	8
781	Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report. <i>Medicine (United States)</i> , 2022, 101, e30719.	0.4	5
782	Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry. <i>Cancer Research Communications</i> , 2022, 2, 1005-1016.	0.7	8
783	A two-step mechanism governing PARP1-DNA retention by PARP inhibitors. <i>Science Advances</i> , 2022, 8, .	4.7	13
784	Effect of the PARP inhibitor veliparib on germ cell tumor cell lines. <i>Oncology Letters</i> , 2022, 24, .	0.8	1
785	Genitourinary tumors. <i>Journal of Surgical Oncology</i> , 2022, 126, 926-932.	0.8	0
786	Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study. <i>Cancer Medicine</i> , 0, , .	1.3	4
787	Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2023, 83, 112-120.	0.9	6
788	PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond. <i>Cancers</i> , 2022, 14, 4332.	1.7	17
790	Metastatic prostate cancer gets into the biomarker era. <i>Canadian Urological Association Journal</i> , 2022, 16, 333.	0.3	0
791	Applications for open access normalized synthesis in metastatic prostate cancer trials. <i>Frontiers in Artificial Intelligence</i> , 0, 5, .	2.0	0
792	Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes. <i>Translational Research</i> , 2022, , .	2.2	0
793	Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. <i>Oncologist</i> , 2022, 27, e783-e795.	1.9	5
794	PARP inhibitors in metastatic prostate cancer: When, who, and how?. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 7, 82-97.	0.0	0
795	Clinical actionability and utilization of next-generation sequencing for prostate cancer in a changing treatment landscape. <i>Frontiers in Urology</i> , 0, 2, .	0.2	1
796	Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
797	External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1857-1861.	1.9	2
798	The Value of Phenotypic Precision Medicine in Prostate Cancer. <i>Oncologist</i> , 2023, 28, 93-104.	1.9	5

#	ARTICLE	IF	CITATIONS
800	Clinical Application of Circulating Tumor DNA Analysis. <i>Laboratory Medicine Online</i> , 2022, 12, 235-243.	0.0	0
801	Modern paradigms for prostate cancer detection and management. <i>Medical Journal of Australia</i> , 2022, 217, 424-433.	0.8	13
802	Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	7
803	Molecular Mechanisms of Castrate-Resistant Prostate Cancer. <i>Urologic Clinics of North America</i> , 2022, 49, 615-626.	0.8	1
804	Prostate cancer treatment “China's perspective. <i>Cancer Letters</i> , 2022, 550, 215927.	3.2	24
805	A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications. <i>European Journal of Medicinal Chemistry Reports</i> , 2022, 6, 100084.	0.6	2
806	Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients. <i>Cancer Control</i> , 2022, 29, 107327482211294.	0.7	28
807	Clinical Relevance of BRCA1/2 Pathogenic Variants and Impaired DNA Repair Pathways in Ovarian Carcinomas. <i>Comprehensive Gynecology and Obstetrics</i> , 2022, , 59-76.	0.0	0
808	Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes. , 2022, 10, e003744.		6
809	Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13003.	1.8	3
810	Concurrent loss of MLH1, PMS2 and MSH6 immunoexpression in digestive system cancers indicating a widespread dysregulation in DNA repair processes. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
811	Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center. <i>Journal of Personalized Medicine</i> , 2022, 12, 1746.	1.1	5
812	Systemic therapy in metastatic hormone-sensitive prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2022, 16, 234-239.	0.5	2
813	The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer. <i>Cancers</i> , 2022, 14, 5305.	1.7	3
815	Optical genome mapping identifies clinically relevant genomic rearrangements in prostate cancer biopsy sample. <i>Cancer Cell International</i> , 2022, 22, .	1.8	6
816	Following the Narrow Path. <i>European Urology</i> , 2022, , .	0.9	0
817	A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	13
818	Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. <i>Journal of Clinical Oncology</i> , 2023, 41, 871-880.	0.8	15

#	ARTICLE	IF	CITATIONS
819	Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	9
820	Oncolytic Virotherapy for Prostate Cancer: Lighting a Fire in Winter. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12647.	1.8	2
821	A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. <i>Nature Cancer</i> , 2022, 3, 1181-1191.	5.7	42
823	Portrait of Molecular Signaling and Putative Therapeutic Targets in Prostate Cancer with ETV4 Fusion. <i>Biomedicines</i> , 2022, 10, 2650.	1.4	0
825	Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .	3.1	25
826	UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 539.e17-539.e22.	0.8	1
827	Comprehensive Clinical and Genetic Analysis of CHEK2 in Croatian Men with Prostate Cancer. <i>Genes</i> , 2022, 13, 1955.	1.0	2
829	Molecular profiling identifies distinct subtypes across TP53 mutant tumors. <i>JCI Insight</i> , 2022, 7, .	2.3	3
830	Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series. <i>International Journal of Clinical Oncology</i> , 0, , .	1.0	1
831	Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance. <i>JCO Precision Oncology</i> , 2022, , .	1.5	3
832	Cribriform pattern in prostate tissues: Predictor for intraductal carcinoma of the prostate based on biopsy and radical prostatectomy pathology. <i>BJUI Compass</i> , 0, , .	0.7	0
833	Molecular Genetics of Prostate Cancer and Role of Genomic Testing. <i>Surgical Pathology Clinics</i> , 2022, 15, 617-628.	0.7	5
834	Integrative Genomic Tests in Clinical Oncology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13129.	1.8	8
835	Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer. <i>Journal of Hepatology</i> , 2023, 78, 333-342.	1.8	5
836	Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective. <i>European Journal of Cancer</i> , 2023, 179, 136-146.	1.3	13
837	Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 50-59.	3.2	8
838	Targeting the tumor stroma for cancer therapy. <i>Molecular Cancer</i> , 2022, 21, .	7.9	71
839	Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1163-1175.	1.1	6

#	ARTICLE	IF	CITATIONS
840	Characteristics of BRCA2 Mutated Prostate Cancer at Presentation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13426.	1.8	5
841	Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and <i>BRCA1</i> , <i>BRCA2</i> , or <i>ATM</i> Alterations Identified by Testing Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2023, 29, 92-99.	3.2	9
842	The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1293-1304.	1.3	0
843	A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer. <i>Biochemical Pharmacology</i> , 2022, 206, 115329.	2.0	16
844	Cancer-cell-intrinsic mechanisms shaping the immunosuppressive landscape of prostate cancer. <i>Asian Journal of Andrology</i> , 2023, 25, 171.	0.8	3
845	Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211315.	1.4	1
846	Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation. <i>Clinical Cancer Research</i> , 2023, 29, 432-445.	3.2	2
847	Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
848	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease. <i>Progres En Urologie</i> , 2022, 32, 1275-1372.	0.3	15
849	<i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects. <i>Clinical Cancer Research</i> , 2023, 29, 422-431.	3.2	3
851	Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma. <i>Cells</i> , 2022, 11, 3563.	1.8	1
852	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance. <i>Progres En Urologie</i> , 2022, 32, 1373-1419.	0.3	5
853	The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational <i>ZENSHIN</i> study. <i>Cancer Medicine</i> , 2023, 12, 5265-5274.	1.3	10
854	Overview on population screening for carriers with germline BRCA mutation in China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
855	Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations. <i>Cancer Management and Research</i> , 0, Volume 14, 3159-3174.	0.9	0
857	Prediction of homologous recombination deficiency from cancer gene expression data. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211336.	0.4	0
858	Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2023, 9, 40.	3.4	22
859	Complexities of Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14257.	1.8	20

#	ARTICLE	IF	CITATIONS
860	Systemic Therapy for Hereditary Breast Cancers. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 203-224.	0.9	1
861	Design and reporting of phase III oncology trials with prospective biomarker validation. <i>Journal of the National Cancer Institute</i> , 0, , .	3.0	1
862	[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study. <i>Clinical Cancer Research</i> , 2023, 29, 1515-1527.	3.2	6
863	Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality. <i>Cancers</i> , 2022, 14, 5795.	1.7	4
864	Exploring new frontiers in prostate cancer research:ÂReport from the 2022 Coffeyâ~Holden prostate cancer academy meeting. <i>Prostate</i> , 2023, 83, 207-226.	1.2	0
865	Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14948.	1.8	2
867	Guidance on the management of adverse reactions induced by poly(ADP-ribose) polymerase inhibitors. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences</i> , 2022, 51, 765-774.	0.1	0
868	Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormoneâ€sensitive prostate cancer. <i>Prostate</i> , 2023, 83, 307-315.	1.2	4
869	Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer. <i>Cancers</i> , 2022, 14, 5922.	1.7	2
870	Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 655-664.	2.0	10
871	Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	8
872	Concordance between single-nucleotide polymorphismâ€based genomic instability assays and a next-generation sequencingâ€based homologous recombination deficiency test. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
873	Cost-effectiveness of PARP inhibitors in malignancies: A systematic review. <i>PLoS ONE</i> , 2022, 17, e0279286.	1.1	1
874	From Concept to Regulatory Drug Approval: Lessons for Theranostics. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1793-1801.	2.8	4
875	Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Meta-analysis. <i>Current Oncology</i> , 2022, 29, 9511-9524.	0.9	3
876	Defektif Homolog Rekombinasyon DNA Tamiri ve PARP Ä°nhibisyonu ArasÄ±ndaki Sentetik Letal EtkileÅŸim. <i>Journal of the Institute of Science and Technology</i> , 0, , 2459-2475.	0.3	0
877	Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patientsâ€a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 665-672.	2.0	6
879	Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?. <i>Cancers</i> , 2022, 14, 6071.	1.7	7

#	ARTICLE	IF	CITATIONS
880	Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
881	The BRCAness Landscape of Cancer. <i>Cells</i> , 2022, 11, 3877.	1.8	5
882	A review of the cost-effectiveness of genetic testing for germline variants in familial cancer. <i>Journal of Medical Economics</i> , 2023, 26, 19-33.	1.0	4
883	The potential of PARP inhibitors in targeted cancer therapy and immunotherapy. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	12
884	Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2023, 28, 366-e224.	1.9	1
885	Prevalence of mutations in DNA repair genes in Russian patients with metastatic castration-resistant prostate cancer. <i>Onkourologiya</i> , 2022, 18, 60-66.	0.1	1
886	Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms. <i>Archives of Medical Research</i> , 2022, 53, 807-817.	1.5	1
887	Plasma progastrinâ€releasing peptide level shows different predictive profiles for treatment response by androgen receptor axisâ€targeted agents in patients with metastatic castrationâ€resistant prostate cancer. <i>Cancer Reports</i> , 0, , .	0.6	1
888	Access of new systemic therapies for Genito-urinary cancers in low-middle income countries. <i>Frontiers in Urology</i> , 0, 2, .	0.2	0
889	Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT. <i>Efficacy and Mechanism Evaluation</i> , 2022, 9, 1-92.	0.9	1
890	Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
891	IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
892	Detection of BRCA1, and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting. <i>Biomedicines</i> , 2022, 10, 3170.	1.4	1
893	Cell-free DNA in the management of prostate cancer: Current status and future prospective. <i>Asian Journal of Urology</i> , 2022, , .	0.5	0
894	Spontaneous Remission of Metastatic Castration-Resistant Prostate Cancer: Coleyâ€™s Toxin Revisited?. <i>Cureus</i> , 2022, , .	0.2	1
895	Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2023, 24, 162-174.	5.1	20
896	E3 ligase ligand optimization of Clinical PROTACs. <i>Frontiers in Chemistry</i> , 0, 11, .	1.8	8
897	Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations. <i>Human Genomics</i> , 2023, 17, .	1.4	3

#	ARTICLE	IF	CITATIONS
898	STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. , 2023, 11, e005627.		17
899	Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer. JCO Precision Oncology, 2023, , .	1.5	5
900	Utilization of genetic testing in men with advanced prostate cancer. Prostate, 2023, 83, 516-523.	1.2	1
901	CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature Communications, 2023, 14, .	5.8	24
902	DDR genes analysis and PARP-inhibitors therapy as tailored management in metastatic prostate cancer: achieved answers, open questions and future perspectives. Minerva Urology and Nephrology, 2023, 74, .	1.3	1
903	Estimating copy number to determine <i>BRCA2</i> deletion status and to expect prognosis in localized prostate cancer. Cancer Medicine, 0, , .	1.3	2
904	The future of patient-derived xenografts in prostate cancer research. Nature Reviews Urology, 2023, 20, 371-384.	1.9	2
905	Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline <i>CHEK2</i> mutation. BMJ Case Reports, 2023, 16, e251320.	0.2	1
906	Polygenic risk score for tumor aggressiveness and early-onset prostate cancer in Asians. Scientific Reports, 2023, 13, .	1.6	0
907	Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches. Cancers, 2023, 15, 461.	1.7	22
908	Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer. JCO Oncology Practice, 2023, 19, e773-e783.	1.4	4
909	Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report. International Cancer Conference Journal, 2023, 12, 131-136.	0.2	4
910	Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology, 2023, 20, 205-216.	1.9	10
911	Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study. BMC Cancer, 2022, 22, .	1.1	4
912	Cancer risk—reducing surgery: Brazilian Society of Surgical Oncology Guideline Part 2 (Gastrointestinal and thyroid). Journal of Surgical Oncology, 2022, 126, 20-27.	0.8	1
913	Research progress of bone metastases: From disease recognition to clinical practice. Frontiers in Oncology, 0, 12, .	1.3	5
914	Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. Molecular Cell, 2023, 83, 660-680.	4.5	10
915	BRCA Gene Mutations and Prostate Cancer. , 0, , .		0

#	ARTICLE	IF	CITATIONS
916	Recent advances in prostate cancer: WNT signaling, chromatin regulation, and transcriptional coregulators. <i>Asian Journal of Andrology</i> , 2023, .	0.8	1
917	Targeting lipid metabolism in metastatic prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311528.	1.4	5
918	Emerging systemic treatment for metastatic castration-resistant prostate cancer: a review of recent randomized controlled trials. <i>Current Opinion in Urology</i> , 2023, 33, 219-229.	0.9	3
919	Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
920	Human papillomavirus E6/E7 oncoproteins promote radiotherapy-mediated tumor suppression by globally hijacking host DNA damage repair. <i>Theranostics</i> , 2023, 13, 1130-1149.	4.6	3
921	DNA repair deficiency as circulating biomarker in prostate cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	8
922	Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis. <i>European Urology Oncology</i> , 2023, 6, 237-250.	2.6	4
923	WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 1095-1101.	0.4	4
924	Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review. <i>World Journal of Men's Health</i> , 2023, 41, 769.	1.7	10
925	Olaparib in Patients With Metastatic Prostate Cancer With <i>BRCA1</i> / <i>BRCA2</i> Mutation: Results From the TAPUR Study. <i>JCO Precision Oncology</i> , 2023, , .	1.5	4
926	Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches. <i>Journal of Personalized Medicine</i> , 2023, 13, 284.	1.1	5
927	Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). <i>Journal of Clinical Oncology</i> , 2023, 41, 3608-3615.	0.8	2
928	Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 3339-3351.	0.8	60
929	Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. <i>Annals of Oncology</i> , 2023, 34, 557-563.	0.6	10
930	A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors. <i>Oncologist</i> , 0, , .	1.9	0
931	Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
932	The Future of Radioligand Therapies in Metastatic Castrate-Resistant Prostate Cancer. <i>Advances in Oncology</i> , 2023, 3, 129-136.	0.1	2
933	Current therapy and drug resistance in metastatic castration-resistant prostate cancer. <i>Drug Resistance Updates</i> , 2023, 68, 100962.	6.5	30

#	ARTICLE	IF	CITATIONS
934	Discovery of a novel 1H-pyrazole- [3,4-b] pyridine-based lysine demethylase 5B inhibitor with potential anti-prostate cancer activity that perturbs the phosphoinositide 3-kinase/AKT pathway. <i>European Journal of Medicinal Chemistry</i> , 2023, 251, 115250.	2.6	1
935	Identification of identical BAP1 mutations in a patient's peritoneal mesothelioma and mucosal melanoma: A precision medicine case study. <i>Human Pathology Reports</i> , 2023, 32, 300705.	0.1	1
936	Loss of CDKN2A/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma. <i>Modern Pathology</i> , 2023, 36, 100150.	2.9	2
937	Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting. <i>European Urology Open Science</i> , 2023, 49, 23-31.	0.2	2
938	Cancer risk-reducing surgery: Brazilian society of surgical oncology guideline part 1 (gynecology and) <i>Tj ETQq0 0 0 rBT /Overlock 10</i>	0.8	1
939	Geriatric assessment in the older adult with genitourinary cancer: A narrative review. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
940	Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2939.	1.8	5
941	Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3083.	1.8	6
942	Comprehensive analysis of germline drivers in endometrial cancer. <i>Journal of the National Cancer Institute</i> , 2023, 115, 560-569.	3.0	4
943	BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature. <i>Journal of Investigative Dermatology</i> , 2023, 143, 1178-1186.	0.3	1
944	Minimally Invasive Urology in the Reiwa Era. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2022, 18, 397-400.	0.0	0
945	Suppression of GCH1 Sensitizes Ovarian Cancer and Breast Cancer to PARP Inhibitor. <i>Journal of Oncology</i> , 2023, 2023, 1-16.	0.6	0
946	Dependence on MUC1-C in Progression of Neuroendocrine Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3719.	1.8	5
947	Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer. <i>Cell Reports Medicine</i> , 2023, 4, 100937.	3.3	11
948	Cardiac glycoside nerifolin exerts anti-cancer activity in prostate cancer cells by attenuating DNA damage repair through endoplasmic reticulum stress. <i>Biochemical Pharmacology</i> , 2023, 209, 115453.	2.0	2
949	Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency. <i>Genomics, Proteomics and Bioinformatics</i> , 2023, , .	3.0	2
950	Atypical ATMs: Broadening the phenotypic spectrum of ATM-associated hereditary cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
951	Prostate cancer and novel pharmacological treatment options-what's new for 2022?. <i>Expert Review of Clinical Pharmacology</i> , 2023, 16, 231-244.	1.3	1

#	ARTICLE	IF	CITATIONS
952	Rucaparib or Physician's Choice in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2023, 388, 719-732.	13.9	104
953	Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 349-356.e2.	0.9	1
954	New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4044.	1.8	0
955	Prognostic value of genomic mutations in metastatic prostate cancer. <i>Heliyon</i> , 2023, 9, e13827.	1.4	3
956	Role of PARP and TRPM2 in VEGF Inhibitor-Induced Vascular Dysfunction. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	3
957	Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. <i>Cancer</i> , 2023, 129, 1411-1418.	2.0	2
959	Urinary DNA as a Tool for Germline and Somatic Mutation Detection in Castration-Resistant Prostate Cancer Patients. <i>Biomedicines</i> , 2023, 11, 761.	1.4	2
960	Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311563.	1.4	8
961	Vaccines as treatments for prostate cancer. <i>Nature Reviews Urology</i> , 2023, 20, 544-559.	1.9	8
962	Progression in immunotherapy for advanced prostate cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
963	Library Screening and Preliminary Characterization of Synthetic Cannabinoids Against Prostate and Pancreatic Cancer Cell Lines. <i>Cannabis and Cannabinoid Research</i> , 0, , .	1.5	0
964	Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis. <i>ESMO Open</i> , 2023, 8, 101154.	2.0	2
966	The biology and treatment of leiomyosarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 184, 103955.	2.0	1
967	Case report: A de novo ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
968	Personalized Systemic Therapies in Hereditary Cancer Syndromes. <i>Genes</i> , 2023, 14, 684.	1.0	4
969	Let's Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5293.	1.8	2
970	A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	3
971	Genomics of Breast Cancer Brain Metastases: A Meta-Analysis and Therapeutic Implications. <i>Cancers</i> , 2023, 15, 1728.	1.7	2

#	ARTICLE	IF	CITATIONS
972	Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 184, 103959.	2.0	0
973	A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
974	Excessive transcription-replication conflicts are a vulnerability of <i>BRCA1</i>-mutant cancers. <i>Nucleic Acids Research</i> , 2023, 51, 4341-4362.	6.5	4
975	Tumor testing and treatment patterns in veterans with metastatic castration-resistant prostate cancer. <i>Seminars in Oncology</i> , 2023, 50, 11-24.	0.8	0
976	NIR-triggerable self-assembly multifunctional nanocarriers to enhance the tumor penetration and photothermal therapy efficiency for castration-resistant prostate cancer. , 2023, 18, .		0
977	Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 366-375.	0.9	10
978	Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	16
979	Delivering Genetic Testing for Patients with Prostate Cancer: Moving Beyond Provider Knowledge as a Barrier to Care. <i>Cancer Control</i> , 2023, 30, .	0.7	0
981	Combining Poly(ADP)-Ribose Polymerase Inhibitors With Abiraterone in Castration-Resistant Prostate Cancer: Is Biomarker Testing Necessary?. <i>Journal of Clinical Oncology</i> , 2023, 41, 3291-3294.	0.8	3
982	Novel breakthroughs in advanced prostate cancer management. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 369-373.	1.1	0
983	Prostate Cancer: Advances in Genetic Testing and Clinical Implications. <i>Uro</i> , 2023, 3, 91-103.	0.3	1
984	Mechanism of PARP inhibitor resistance and potential overcoming strategies. <i>Genes and Diseases</i> , 2024, 11, 306-320.	1.5	7
986	Molecular testing of DNA damage response pathways in prostate cancer patients. <i>Current Opinion in Oncology</i> , 2023, 35, 224-230.	1.1	0
987	A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2357-2373.	2.0	3
988	Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients. <i>Journal of Urology</i> , 2023, 209, 918-927.	0.2	1
989	Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2023, , .	1.5	1
990	An approach to genetic testing in patients with metastatic castration-resistant prostate cancer in Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2023, 52, 135-148.	0.2	1
991	Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study. <i>Oncologist</i> , 2023, 28, e737-e747.	1.9	2

#	ARTICLE	IF	CITATIONS
992	Re: Pain and Health-related Quality of Life with Olaparib Versus Physician's Choice of Next-generation Hormonal Drug in Patients with Metastatic Castration-resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations (PROfound): An Open-label, Randomised, Phase 3 Trial. <i>European Urology</i> , 2023, , .	0.9	0
993	ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems. <i>Communications Biology</i> , 2023, 6, .	2.0	2
994	Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond. <i>Current Oncology</i> , 2023, 30, 4246-4256.	0.9	7
995	PARP Inhibitors in Breast and Ovarian Cancer. <i>Cancers</i> , 2023, 15, 2357.	1.7	9
996	Ibrutinib Inhibits BTK Signaling in Tumor-Infiltrated B Cells and Amplifies Antitumor Immunity by PD-1 Checkpoint Blockade for Metastatic Prostate Cancer. <i>Cancers</i> , 2023, 15, 2356.	1.7	0
997	PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. <i>European Urology</i> , 2023, 84, 253-256.	0.9	8
998	Targeted therapy. , 2023, , 205-411.		0
999	Use of PARP inhibitors in prostate cancer: from specific to broader application. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	2
1029	Genetic Contributions and Personalized Medicine. , 2023, , 3-17.		0
1051	Guidelines for genetic testing in prostate cancer: a scoping review. <i>Prostate Cancer and Prostatic Diseases</i> , 0, , .	2.0	5
1117	Molecular tumour boards " current and future considerations for precision oncology. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 843-863.	12.5	6
1155	SIUR best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 0, , .	1.4	1
1160	Metastatic Prostate Cancer. , 2023, , 241-255.		0
1162	Metastasiertes kastrationsresistentes Prostatakarzinom mit Therapiesequenz (mCRPC). , 2023, , 77-92.		0
1163	Epidemiologie des metastasierten Prostatakarzinoms. , 2023, , 1-6.		0
1178	Novel treatment strategies to overcome resistance in prostate cancer. , 2024, , 289-308.		0
1179	Overcoming resistance in prostate cancer with targeted and small molecule-based therapies. , 2024, , 255-287.		0
1206	Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer. <i>Cancer Treatment and Research</i> , 2023, , 103-124.	0.2	0

#	ARTICLE	IF	CITATIONS
1207	Case Study #8: Alpha-Therapy with Radium-223 Dichloride for Metastatic Castration-Resistant Prostate Cancer. , 2023, , 387-405.		0
1208	Case Study #7: PSMA-617. , 2023, , 369-386.		0
1210	Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis. Targeted Oncology, 0, , .	1.7	1
1213	Re: Abiraterone and Olaparib for Metastatic Castration-resistant Prostate Cancer. European Urology, 2023, , .	0.9	0
1229	Handling Germline Findings in Ovarian Cancer Cases. , 2023, , 129-141.		0
1250	Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer. Npj Genomic Medicine, 2024, 9, .	1.7	0
1269	Editorial: Expert opinions in genitourinary oncology. Frontiers in Oncology, 0, 13, .	1.3	0
1291	Malignome des Urogenitaltrakts. , 2024, , 801-864.		0
1315	Pharmacogenomics and Precision Therapy in Prostate Cancer: Challenges and Perspectives. , 2024, , 335-377.		0
1324	Urologische Tumoren. , 2024, , 239-274.		0
1326	Biological Markers of Therapeutic Response in Prostate Cancer. , 2024, , 221-241.		0
1327	Genetic Susceptibility to Prostate Cancer. , 2024, , 21-42.		0